Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12123987 | 0.87 | KCNH2 (0.47) | KCNH2NOS1NOS2CXCR4NPSR1 | |
| SCHEMBL10119370 | 0.86 | KCNH2 (0.52) | KCNH2NOS1NOS2HIF1AEPAS1 | |
| SCHEMBL21485103 | 0.85 | KCNH2 (0.76) | KCNH2NOS1NOS2CXCR4NPSR1 | |
| SCHEMBL21879600 | 0.83 | KCNH2 (0.73) | KCNH2NOS1NOS2CXCR4NPSR1 | |
| Lithium SCHEMBL30464084 | 0.83 | KCNH2 (0.73) | KCNH2NOS1NOS2CXCR4NPSR1 | |
| SCHEMBL10141770 | 0.81 | KCNH2 (0.84) | KCNH2CYP19A1 | |
| SCHEMBL21899739 | 0.79 | KCNH2 (0.88) | KCNH2CYP19A1 | |
| SCHEMBL12445671 | 0.79 | KCNH2 (0.73) | KCNH2NOS1NOS2CXCR4NPSR1 | |
| SCHEMBL18858526 | 0.78 | KCNH2 (0.48) | KCNH2NOS1NOS2NPSR1SYK | |
| SCHEMBL21485098 | 0.78 | KCNH2 (0.85) | KCNH2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNH2 3887/4885NOS1 1084/4885NOS2 1041/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNH2 3887/4885NOS1 1084/4885NOS2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.